Pull to refresh
Logo
PAVmed's Lucid begins collecting Medicare payments for EsoGuard

PAVmed's Lucid begins collecting Medicare payments for EsoGuard

Money Moves

Parent reports a wider GAAP loss as device subsidiaries advance toward FDA milestones

Overview

Updated 1 hour ago

For years, Lucid Diagnostics' EsoGuard test for esophageal precancer had no guaranteed Medicare payer. In October, Lucid began collecting Medicare payments for the test, and October was its best month for volume.

The milestone lands on a thin balance sheet. PAVmed reported an $11.8 million GAAP net loss for the third quarter and held $8.9 million in cash, $5.3 million of it restricted. Its $15 million senior note carries a collateral covenant tied to Lucid's share price.

Why it matters

Medicare covers about half the 30 million Americans guidelines recommend for esophageal precancer testing, so reimbursement decides whether EsoGuard becomes a business.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Key Indicators

2,871
EsoGuard tests performed in Q3 2026
Lucid ran 2,871 tests in the quarter ended September 30, 2026.
$1.2M
EsoGuard revenue in Q3 2026
Revenue recognized on EsoGuard testing for the quarter.
1,800+
EsoGuard tests in October 2026
October was a record month for test volume.
$1.2M
Non-GAAP adjusted net loss, Q3 2026
Loss excluding stock compensation and noncash fair-value changes.
$8.9M
Cash and equivalents, September 30, 2026
Includes $5.3 million of restricted cash held as collateral.
$11.8M
GAAP net loss attributable to common stockholders, Q3 2026
Driven largely by a noncash mark-to-market charge on Lucid shares.
15%
PAVmed's stake in Lucid common shares
PAVmed holds about 25% of Lucid's voting interest.

Voices

Curated perspectives — historical figures and your fellow readers.

Sign up to generate historical perspectives on this story.

People Involved

Organizations Involved

Timeline

August 2026 November 2026

9 events Latest: 3 days ago
Tap a bar to jump to that date
  1. PAVmed reports Q3 2026 results and business update

    Latest Financial

    PAVmed reported a $1.2 million non-GAAP adjusted loss and detailed portfolio progress.

  2. Lucid reports Q3 results and billing milestones

    Financial

    Lucid announced a new Category III CPT code for EsoCheck cell collection.

  3. Lucid begins receiving Medicare payments

    Reimbursement

    Lucid started collecting Medicare payments for EsoGuard through contractor Novitas.

  4. October sets EsoGuard volume record

    Commercial

    Lucid performed more than 1,800 EsoGuard tests in October, a record month.

  5. Veris starts implantable monitor animal study

    Clinical

    Veris began a 90-day animal study after design freeze on its implantable monitor.

  6. PortIO holds initial FDA meeting

    Regulatory

    PAVmed held an initial FDA meeting on PortIO, with a formal pre-submission meeting set for January 2027.

  7. Q3 closes with $8.9 million in cash

    Financial

    PAVmed held $8.9 million in cash, $5.3 million restricted; Lucid shares closed at $0.75.

  8. New at-the-market facility established

    Financing

    PAVmed set up a $9.4 million at-the-market facility with A.G.P.

  9. PAVmed funds senior note amendment

    Financing

    PAVmed funded a $15 million senior secured note amendment, placing $5 million in a collateral account.

Scenarios

1

Veris implantable monitor reaches FDA submission in early 2027

Possible Resolves by Q2 2027

Discussed by: PAVmed management

Veris reached design freeze on its implantable monitor and started a 90-day animal study in October. Management says the device is on track for an early 2027 FDA submission. A clearance would also make about $2.5 million of Veris warrants callable.

2

PAVmed raises more capital as cash runway tightens

Likely Resolves by Q2 2027

Discussed by: PAVmed management on the Q3 earnings call

PAVmed ended September with $8.9 million in cash, $5.3 million of it restricted, and a quarterly burn near $2.8 million. It has a $9.4 million at-the-market facility available. Drawing on it or raising new capital would extend the runway.

3

Lucid's Medicare revenue scales as EsoGuard volume grows

Possible Resolves by Q2 2027

Discussed by: PAVmed and Lucid management

Lucid performed 2,871 EsoGuard tests and recognized $1.2 million in revenue in the third quarter. October set a record above 1,800 tests. Continued Medicare collections would turn volume into recurring revenue.

4

Senior note collateral covenant forces a restructuring

Unlikely Resolves by Feb 28, 2027

Discussed by: PAVmed management

The $15 million senior note's collateral coverage covenant was not met at September 30 after Lucid's share price fell to $0.75. The noteholder waived the covenant through the SEC filing date. A further decline could force renegotiation.

Historical Context

2 moments from history that rhyme with this story — and how they unfolded.

August 2014

Cologuard and Medicare coverage (2014)

Exact Sciences won FDA approval for Cologuard, a stool-based colon cancer test, in August 2014. A Medicare coverage decision followed, giving the test a payer pathway.

Then

Cologuard became Exact Sciences' core product.

Now

It showed that a noninvasive diagnostic can scale once Medicare pays for it.

Why this matters now

EsoGuard is trying to make the same jump from test to reimbursed product.

2024

DermTech's reimbursement struggle (2024)

DermTech, which sold a genomic melanoma test, struggled to win payer coverage and filed for Chapter 11 bankruptcy protection in 2024.

Then

The company wound down its operations.

Now

It became a cautionary case for diagnostics that scale before reimbursement.

Why this matters now

EsoGuard now has Medicare payment, the hurdle DermTech never cleared.

Sources

(5)